{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:07:21Z","timestamp":1794546441644,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"Abstract<\/jats:title>\n \n Purpose<\/jats:title>\n \n This study aimed to investigate the ability of Al\n 18<\/jats:sup>\n F-NOTA-FAPI PET\/CT to diagnose pancreatic carcinoma and tumor-associated inflammation with the comparison of\n 18<\/jats:sup>\n F-FDG PET\/CT.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Prospective analysis of Al\n 18<\/jats:sup>\n F-NOTA-FAPI PET\/CT and\n 18<\/jats:sup>\n F-FDG PET\/CT scans of 31 patients from 05\/2021 to 05\/2022 were analyzed. Al\n 18<\/jats:sup>\n F-NOTA-FAPI imaging was performed in patients who had Ce-CT and FDG PET\/CT and the diagnosis was still unclear. Follow-up histopathology or radiographic examination confirmed the findings. Radiotracer uptake, diagnostic performance, and TNM (tumor-node-metastasis) classifications were compared.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 31 patients with pancreatic carcinoma (all were adenocarcinoma) underwent Al\n 18<\/jats:sup>\n F-NOTA-FAPI-04 PET\/CT, including 20 male and 11 female patients, with a mean age of 58.2\u2009\u00b1\u20098.5\u00a0years. FAPI-04 PET\/CT imaging showed a higher value of SUV\n max-15min\/30min\/60min<\/jats:sub>\n , SUV\n mean-15min\/30min\/60min<\/jats:sub>\n , TBR\n 1<\/jats:sub>\n , and TBR\n 2<\/jats:sub>\n in pancreatic carcinoma than FDG (all\n P<\/jats:italic>\n \u2009<\u20090.01). The mean level of Al\n 18<\/jats:sup>\n F-NOTA FAPI-04 uptake values of the pancreatic ductal adenocarcinoma was higher than that of pancreatitis in both SUV\n max-30min<\/jats:sub>\n (\n P<\/jats:italic>\n \u2009<\u20090.01)\n ,<\/jats:sub>\n SUV\n mean-30min<\/jats:sub>\n (\n P<\/jats:italic>\n \u2009<\u20090.05), SUV\n max-60min<\/jats:sub>\n (\n P<\/jats:italic>\n \u2009<\u20090.01)\n ,<\/jats:sub>\n and SUV\n mean-60min<\/jats:sub>\n (\n P<\/jats:italic>\n \u2009<\u20090.01). The FAPI \u25b3SUV\n max-1<\/jats:sub>\n , \u25b3SUV\n max-2<\/jats:sub>\n , and \u25b3SUV\n mean-2<\/jats:sub>\n uptake values of pancreatic carcinoma were higher than tumor-associated inflammation (all\n P<\/jats:italic>\n \u2009<\u20090.01). TNM staging of 16\/31 patients changed after Al\n 18<\/jats:sup>\n F-NOTA FAPI-04 PET\/CT examination with all upstaging changes.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n Al\n 18<\/jats:sup>\n F-NOTA-FAPI-04 PET\/CT at 15 and 30\u00a0min also demonstrated an equivalent detection ability of pancreatic lesion to\n 18<\/jats:sup>\n F-FDG PET\/CT. Delayed-phase Al\n 18<\/jats:sup>\n F-NOTA-FAPI-04 PET\/CT can help differentiate pancreatic carcinoma and tumor-associated inflammation. Al\n 18<\/jats:sup>\n F-NOTA FAPI-04 PET\/CT also performed better than FDG PET\/CT in TNM staging.\n <\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n \n Chinese Clinical Trial Registry, ChiCTR2100051406. Registered 23 September 2021,\n https:\/\/www.chictr.org.cn\/showproj.html?proj=133033<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s40644-023-00596-1","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T06:02:46Z","timestamp":1694498566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Clinical application of Al18F-NOTA-FAPI PET\/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to 18F-FDG"],"prefix":"10.1186","volume":"23","author":[{"given":"Zhehao","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjiu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"issue":"1","key":"596_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA. 2023;73(1):17\u201348.","journal-title":"CA"},{"issue":"6","key":"596_CR2","first-page":"557","volume":"12","author":"VX Nguyen","year":"2011","unstructured":"Nguyen VX, Nguyen CC, Nguyen BD. 18F-FDG PET\/CT imaging of the pancreas: spectrum of diseases. JOP. 2011;12(6):557\u201366.","journal-title":"JOP"},{"issue":"19","key":"596_CR3","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3748\/wjg.v24.i19.2047","volume":"24","author":"L Zhang","year":"2018","unstructured":"Zhang L, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer. World J Gastroenterol. 2018;24(19):2047\u201360.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"596_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00261-017-1374-2","volume":"43","author":"R Yeh","year":"2018","unstructured":"Yeh R, Dercle L, Garg I, Wang ZJ, Hough DM, Goenka AH. The Role of 18F-FDG PET\/CT and PET\/MRI in Pancreatic Ductal Adenocarcinoma. Abdominal Radiol (New York). 2018;43(2):415\u201334.","journal-title":"Abdominal Radiol (New York)"},{"issue":"3","key":"596_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Kratochwil C, Lindner T, et al. (68)Ga-FAPI PET\/CT: Biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nuclear Med. 2019;60(3):386\u201392.","journal-title":"J Nuclear Med"},{"issue":"7","key":"596_CR6","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1053\/j.gastro.2018.12.044","volume":"156","author":"MC Whittle","year":"2019","unstructured":"Whittle MC, Hingorani SR. Fibroblasts in pancreatic ductal adenocarcinoma: biological mechanisms and therapeutic targets. Gastroenterology. 2019;156(7):2085\u201396.","journal-title":"Gastroenterology"},{"issue":"1","key":"596_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-017-0448-5","volume":"10","author":"D von Ahrens","year":"2017","unstructured":"von Ahrens D, Bhagat TD, Nagrath D, Maitra A, Verma A. The role of stromal cancer-associated fibroblasts in pancreatic cancer. J Hematol Oncol. 2017;10(1):76.","journal-title":"J Hematol Oncol"},{"issue":"18","key":"596_CR8","doi-asserted-by":"publisher","first-page":"5072","DOI":"10.7150\/thno.26546","volume":"8","author":"Q Sun","year":"2018","unstructured":"Sun Q, Zhang B, Hu Q, et al. The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. Theranostics. 2018;8(18):5072\u201387.","journal-title":"Theranostics"},{"issue":"8","key":"596_CR9","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1007\/s00259-022-05729-5","volume":"49","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Jia G, Pan G, et al. Comparison of the diagnostic efficacy of (68) Ga-FAPI-04 PET\/MR and (18)F-FDG PET\/CT in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49(8):2877\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"596_CR10","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00259-019-04654-4","volume":"47","author":"L Zhao","year":"2020","unstructured":"Zhao L, Zhuang Y, Fu K, et al. Usefulness of [(18)F]fluorodeoxyglucose PET\/CT for evaluating the PD-L1 status in nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2020;47(5):1065\u201374.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"596_CR11","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1007\/s00259-021-05470-5","volume":"48","author":"S Wang","year":"2021","unstructured":"Wang S, Zhou X, Xu X, et al. Clinical translational evaluation of Al(18)F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging. Eur J Nucl Med Mol Imaging. 2021;48(13):4259\u201371.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"596_CR12","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","volume":"47","author":"H Chen","year":"2020","unstructured":"Chen H, Pang Y, Wu J, et al. Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47(8):1820\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"596_CR13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2967\/jnumed.120.253062","volume":"62","author":"M R\u00f6hrich","year":"2021","unstructured":"R\u00f6hrich M, Naumann P, Giesel FL, et al. Impact of (68)Ga-FAPI PET\/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J Nuclear Med. 2021;62(6):779\u201386.","journal-title":"J Nuclear Med"},{"issue":"5","key":"596_CR14","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s00261-007-9298-x","volume":"32","author":"EP Tamm","year":"2007","unstructured":"Tamm EP, Loyer EM, Faria SC, Evans DB, Wolff RA, Charnsangavej C. Retrospective analysis of dual-phase MDCT and follow-up EUS\/EUS-FNA in the diagnosis of pancreatic cancer. Abdom Imaging. 2007;32(5):660\u20137.","journal-title":"Abdom Imaging"},{"issue":"3","key":"596_CR15","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1148\/radiol.2243011284","volume":"224","author":"RW Prokesch","year":"2002","unstructured":"Prokesch RW, Chow LC, Beaulieu CF, Bammer R, Jeffrey RB Jr. Isoattenuating pancreatic adenocarcinoma at multi-detector row CT: secondary signs. Radiology. 2002;224(3):764\u20138.","journal-title":"Radiology"},{"issue":"4","key":"596_CR16","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1148\/rg.324115143","volume":"32","author":"DV Sahani","year":"2012","unstructured":"Sahani DV, Bonaffini PA, Catalano OA, Guimaraes AR, Blake MA. State-of-the-art PET\/CT of the pancreas: current role and emerging indications. Radiographics. 2012;32(4):1133\u201358 (discussion 58-60).","journal-title":"Radiographics"},{"issue":"2","key":"596_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1148\/radiol.2382041977","volume":"238","author":"GK von Schulthess","year":"2006","unstructured":"von Schulthess GK, Steinert HC, Hany TF. Integrated PET\/CT: current applications and future directions. Radiology. 2006;238(2):405\u201322.","journal-title":"Radiology"},{"issue":"8","key":"596_CR18","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3390\/cancers11081052","volume":"11","author":"I Gonz\u00e1lez-Borja","year":"2019","unstructured":"Gonz\u00e1lez-Borja I, Vi\u00fadez A, Go\u00f1i S, et al. Omics Approaches in pancreatic adenocarcinoma. Cancers. 2019;11(8):1052.","journal-title":"Cancers"},{"issue":"4","key":"596_CR19","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1007\/s00259-021-05576-w","volume":"49","author":"Y Pang","year":"2022","unstructured":"Pang Y, Zhao L, Shang Q, et al. Positron emission tomography and computed tomography with [(68)Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49(4):1322\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"596_CR20","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.2967\/jnumed.121.263736","volume":"63","author":"A Pirasteh","year":"2022","unstructured":"Pirasteh A, Periyasamy S, Meudt JJ, et al. Staging liver fibrosis by fibroblast activation protein inhibitor PET in a human-sized swine model. J Nuclear Med. 2022;63(12):1956\u201361.","journal-title":"J Nuclear Med"},{"issue":"4","key":"596_CR21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jcmgh.2022.12.005","volume":"15","author":"AT Yang","year":"2023","unstructured":"Yang AT, Kim YO, Yan XZ, et al. Fibroblast Activation protein activates macrophages and promotes parenchymal liver inflammation and fibrosis. Cell Mol Gastroenterol Hepatol. 2023;15(4):841\u201367.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"4","key":"596_CR22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3390\/cancers13040796","volume":"13","author":"J Liermann","year":"2021","unstructured":"Liermann J, Syed M, Ben-Josef E, et al. Impact of FAPI-PET\/CT on target volume definition in radiation therapy of locally recurrent pancreatic cancer. Cancers. 2021;13(4):796.","journal-title":"Cancers"},{"issue":"6","key":"596_CR23","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2967\/jnumed.121.262808","volume":"63","author":"L Kessler","year":"2022","unstructured":"Kessler L, Ferdinandus J, Hirmas N, et al. Pitfalls and common findings in (68)Ga-FAPI PET: a pictorial analysis. J Nuclear Med. 2022;63(6):890\u20136.","journal-title":"J Nuclear Med"},{"issue":"1142","key":"596_CR24","doi-asserted-by":"publisher","first-page":"20220463","DOI":"10.1259\/bjr.20220463","volume":"96","author":"M Hotta","year":"2023","unstructured":"Hotta M, Rieger AC, Jafarvand MG, et al. Non-oncologic incidental uptake on FAPI PET\/CT imaging. Br J Radiol. 2023;96(1142):20220463.","journal-title":"Br J Radiol"},{"issue":"12","key":"596_CR25","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1007\/s12149-021-01673-w","volume":"35","author":"S Zheng","year":"2021","unstructured":"Zheng S, Lin R, Chen S, et al. Characterization of the benign lesions with increased (68)Ga-FAPI-04 uptake in PET\/CT. Ann Nucl Med. 2021;35(12):1312\u201320.","journal-title":"Ann Nucl Med"},{"issue":"1","key":"596_CR26","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1097\/RLU.0000000000003896","volume":"47","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wu J, Liu L, Peng D, Chen Y. 68Ga-FAPI-04 PET\/CT imaging for fibrous dysplasia of the bone. Clin Nucl Med. 2022;47(1):e9\u201310.","journal-title":"Clin Nucl Med"},{"issue":"5","key":"596_CR27","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/RLU.0000000000003996","volume":"47","author":"H Liu","year":"2022","unstructured":"Liu H, Fu W, Yang X, Chen Y. Increased 68Ga-FAPI uptake in avascular necrosis of femoral head in a patient with nasopharyngeal carcinoma. Clin Nucl Med. 2022;47(5):449\u201350.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"596_CR28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/RLU.0000000000003990","volume":"47","author":"W Gong","year":"2022","unstructured":"Gong W, Yang X, Mou C, Liu H, Zhang C. Bone tuberculous granulomatous inflammation mimicking malignancy on 68Ga-FAPI PET\/CT. Clin Nucl Med. 2022;47(4):348\u20139.","journal-title":"Clin Nucl Med"},{"issue":"7","key":"596_CR29","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1097\/RLU.0000000000004213","volume":"47","author":"W Gong","year":"2022","unstructured":"Gong W, Chen S, He L, Liu W, Zhang C. Intense 68Ga-FAPI uptake in a patient with myositis ossificans: mimicking bone malignancy. Clin Nucl Med. 2022;47(7):638\u20139.","journal-title":"Clin Nucl Med"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-023-00596-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-023-00596-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-023-00596-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T16:04:08Z","timestamp":1700582648000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-023-00596-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["596"],"URL":"https:\/\/doi.org\/10.1186\/s40644-023-00596-1","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]},"assertion":[{"value":"1 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical translational study was approved by our institutional Ethics Committee (approval No. 2021XJSS01) and registered in the Chinese Clinical Trial Registry (ChiCTR2100051406).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}